Head to Head Survey: Daiichi Sankyo (OTCMKTS:DSNKY) vs. ANI Pharmaceuticals (NASDAQ:ANIP)

ANI Pharmaceuticals (NASDAQ:ANIP) and Daiichi Sankyo (OTCMKTS:DSNKY) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, risk, valuation, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for ANI Pharmaceuticals and Daiichi Sankyo, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ANI Pharmaceuticals	0	4	4	0	2.50
Daiichi Sankyo	1	1	0	0	1.50

ANI Pharmaceuticals presently has a consensus price target of $105.83, suggesting a potential upside of 44.59%. Given ANI Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts clearly believe ANI Pharmaceuticals is more favorable than Daiichi Sankyo.

Volatility and Risk

ANI Pharmaceuticals has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Daiichi Sankyo has a beta of -0.18, indicating that its stock price is 118% less volatile than the S&P 500.

Insider & Institutional Ownership

76.0% of ANI Pharmaceuticals shares are owned by institutional investors. 8.1% of ANI Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares ANI Pharmaceuticals and Daiichi Sankyo”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ANI Pharmaceuticals	$883.37 million	1.90	$78.34 million	$4.64	15.77
Daiichi Sankyo	$14.10 billion	2.42	$1.72 billion	$0.86	21.28

Daiichi Sankyo has higher revenue and earnings than ANI Pharmaceuticals. ANI Pharmaceuticals is trading at a lower price-to-earnings ratio than Daiichi Sankyo, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ANI Pharmaceuticals and Daiichi Sankyo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
ANI Pharmaceuticals	11.07%	27.37%	10.47%
Daiichi Sankyo	10.92%	14.35%	6.10%

Summary

ANI Pharmaceuticals beats Daiichi Sankyo on 10 of the 14 factors compared between the two stocks.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

About Daiichi Sankyo

Daiichi Sankyo Company, Limited manufactures, markets, and sells pharmaceutical products worldwide. The company offers Enhertu, a HER2 directed antibody drug conjugate; Turalio, a CSF-1R inhibitor; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with relapsed/refractory FLT3-ITD acute myeloid leukemia; ferric carboxymaltose injection for treating anaemia; and Injectafer for the treatment for iron deficiency anaemia. It also provides olmesartan medoxomil antihypertensive agents; NILEMDO, an oral treatment to help in lowering cholesterol; and Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe for reducing cholesterol. In addition, the company offers Canalia for the treatment of type 2 diabetes mellitus; Emgalty for the treatment of migraine attacks; Pralia for the treatment of anti-osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark for the treatment of bone complications caused by bone metastasis from tumors; Tarlige for treating pain; Tenelia for the treatment of Type 2 diabetes mellitus; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-epileptic agent. Further, it provides vaccines for influenza, measles/rubella infection, and mumps. The company has a development and commercialization agreement with Merck to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates The company was founded in 1899 and is headquartered in Tokyo, Japan.